Tin tức & Cập nhật
Xem bài viết Dược
Xem

Statin-ezetimibe holds slight advantage over PCSK9is in ACS
In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).
Statin-ezetimibe holds slight advantage over PCSK9is in ACS
24 Apr 2026
Deuruxolitinib improves scalp hair regrowth in patients with severe AA
Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.
Deuruxolitinib improves scalp hair regrowth in patients with severe AA
23 Apr 2026
Bax24 data boost baxdrostat potential for resistant HTN
The results of the phase III Bax24 trial underpin the efficacy of baxdrostat, a selective aldosterone synthase inhibitor (ASI), for the treatment of uncontrolled or resistant hypertension (HTN).
Bax24 data boost baxdrostat potential for resistant HTN
21 Apr 2026
Fluvoxamine improves fatigue, QoL in long COVID patients
Patients with long COVID may derive benefits from treatment with fluvoxamine, which has been shown to reduce fatigue and improve quality of life (QoL) in a study. The use of metformin, on the other hand, shows no significant advantage.





